# Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

> **NCT07592273** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 576 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Surabgene Lomparvovec
- **DRUG:** Sham
- **DRUG:** Topical Steroid
- **DRUG:** Artificial Tears

## Key facts

- **NCT ID:** NCT07592273
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2028-06
- **Final completion:** 2036-02
- **Target enrollment:** 576 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07592273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07592273, "Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07592273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*